Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The company will address the observations and respond to the U.S. FDA within the stipulated timeframe
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
DiaMedica said it plans to launch the trial later in 2026
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The company announced positive topline data from the Phase II ZUPREME-1 trial
Subscribe To Our Newsletter & Stay Updated
